RB0 Stock Overview
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
REGENXBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.50 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$4.68 |
| Beta | 1.11 |
| 1 Month Change | 42.86% |
| 3 Month Change | 6.92% |
| 1 Year Change | -45.51% |
| 3 Year Change | -55.03% |
| 5 Year Change | -77.59% |
| Change since IPO | -60.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| RB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.9% | 1.1% | 3.4% |
| 1Y | -45.5% | -14.9% | 15.0% |
Return vs Industry: RB0 underperformed the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: RB0 underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| RB0 volatility | |
|---|---|
| RB0 Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: RB0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RB0's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 353 | Curran Simpson | www.regenxbio.com |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.
REGENXBIO Inc. Fundamentals Summary
| RB0 fundamental statistics | |
|---|---|
| Market cap | €430.00m |
| Earnings (TTM) | -€199.65m |
| Revenue (TTM) | €73.25m |
4.8x
P/S Ratio-1.7x
P/E RatioIs RB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RB0 income statement (TTM) | |
|---|---|
| Revenue | US$83.33m |
| Cost of Revenue | US$33.57m |
| Gross Profit | US$49.76m |
| Other Expenses | US$276.86m |
| Earnings | -US$227.10m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 12, 2025
| Earnings per share (EPS) | -4.53 |
| Gross Margin | 59.72% |
| Net Profit Margin | -272.54% |
| Debt/Equity Ratio | 23.0% |
How did RB0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 23:38 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
REGENXBIO Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |